The content of this website is intended for healthcare professionals only

High morbidity found in adult survivors of childhood cancer

95% have chronic health condition by 45 years

Jo Carlowe

Wednesday, 12 June 2013

Adult survivors of childhood cancers have a high prevalence of chronic health conditions, new research has found.

In an analysis that included more than 1,700 adult survivors of childhood cancer, researchers found a very high percentage of survivors with 1 or more chronic health conditions, with an estimated cumulative prevalence of any chronic health condition of 95% at age 45 years, according to a study in this week’s issue of JAMA.

The researchers called for ongoing clinical evaluation to advance the knowledge about the influence of aging on cancer-related morbidity and mortality in this group.

“Curative therapy for paediatric malignancies has produced a growing population of adults formerly treated for childhood cancer who are at risk for health problems that appear to increase with aging. The prevalence of cancer-related toxic effects that are systematically ascertained through formal clinical assessments has not been well studied,” say the authors.

Melissa M. Hudson, M.D., of St. Jude Children's Research Hospital and the University of Tennessee College of Medicine, Memphis, and colleagues conducted a study to determine, through systematic comprehensive medical assessment, the general health status of long-term survivors of childhood cancer and the prevalence of treatment complications following predisposing cancer treatment-related exposures.

The presence of health outcomes was ascertained using systematic exposure-based medical assessments among 1,713 adult (median [midpoint] age, 32 years) survivors of childhood cancer (median time from diagnosis, 25 years) enrolled in the St. Jude Lifetime Cohort Study since October 1, 2007, and undergoing follow-up through October 31, 2012. The participants were diagnosed and treated between 1962 and 2001. The primary measured outcomes were the age-specific cumulative prevalence of adverse outcomes by organ system.

The researchers found that impaired pulmonary, auditory, cardiac, endocrine, and nervous system function were most prevalent (detected in 20% or more of participants at risk). The crude prevalence of adverse health outcomes was highest for pulmonary (abnormal pulmonary function, 65.2%), auditory (hearing loss, 62.1%) endocrine or reproductive (any endocrine condition, such as hypothalamic-pituitary axis disorders and male germ cell dysfunction, 62%), cardiac (any cardiac condition, such as heart valve disorders, 56.4%), and neurocognitive (neurocognitive impairment, 48%) function.

“Among survivors at risk for adverse outcomes following specific cancer treatment modalities, the estimated cumulative prevalence at age 50 years was 21.6% for cardiomyopathy, 83.5% for heart valve disorder, 81.3% for pulmonary dysfunction, 76.8% for pituitary dysfunction, 86.5% for hearing loss, 31.9% for primary ovarian failure, 31.1% for Leydig cell failure, and 40.9% for breast cancer,” the authors write.

Abnormalities involving hepatic, skeletal, renal, and hematopoietic function were less common (less than 20%).

“In this clinically evaluated cohort, 98.2% of participants had a chronic health condition,” the researchers note.

“The overall cumulative prevalence of a chronic condition was estimated to be 95.5% by age 45 years and 93.5% 35 years after cancer diagnosis.”

At age 45 years, the estimated cumulative prevalence was 80.5% for a serious/disabling or life-threatening chronic condition.

“The percentage of survivors with one or more chronic health conditions prevalent in a young adult population was extraordinarily high,” say the authors.

They called for better and earlier monitoring for adults who survived cancer in childhood.

“These data underscore the need for clinically focused monitoring, both for conditions that have significant morbidity if not detected and treated early, such as second malignancies and heart disease, and also for those that if remediated can improve quality of life, such as hearing loss and vision deficits,” they said.

Registered in England and Wales. Reg No. 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Reg No. 30158470